Healthcare / BiotechnologyParis
$2.96
+0.20 (+7.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-19.8M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$56M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-279.6%
↓Gross Margin
61.1%
↑Debt/Equity
1.54
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+49.0%
FCF CAGR
—
FCF margin
-708.8%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.2M · net income $-28.9M · FCF $-22.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.2M | $3.2M | $2.2M | $1.4M | $972000.00 |
| Net Income | $-28.9M | $-28.9M | $-19.7M | $-13.7M | $-9.0M |
| EBITDA | $-26.3M | $-26.3M | $-18.4M | $-13.1M | $-8.6M |
| EPS | -2.20 | -2.20 | -1.70 | -1.40 | -3.70 |
| Gross Margin | 61.1% | 61.1% | 74.3% | 76.3% | 82.9% |
| Operating Margin | -884.0% | -884.0% | -895.2% | -948.0% | -914.8% |
| Net Margin | -898.8% | -898.8% | -885.0% | -959.0% | -927.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.54 | 1.54 | 0.69 | 0.42 | 0.15 |
| Current Ratio | 1.94 | 1.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-22.8M | $-22.8M | $-19.8M | $-13.3M | $-8.2M |
| Returns | |||||
| ROE | -279.6% | -279.6% | -96.3% | -51.1% | -22.6% |
| Valuation | |||||
| P/B | 3.75 | 3.75 | 4.16 | 3.28 | 0.82 |
| Growth & Yield | |||||
| Revenue Growth | 44.3% | 44.3% | 55.8% | 47.1% | — |
| EPS Growth | -29.4% | -29.4% | -21.4% | 62.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-45.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.70 → -2.20
Residual
-45.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.